DYN
Dyne Therapeutics, Inc. · Healthcare · Biotechnology
Semua angka kepemilikan: hanya manajer 13F yang dipantau, posisi saham biasa, periode pelaporan Q2 2024
| Kuartal | Pemegang | Δ | Saham | Nilai yang dilaporkan | Baru | Keluar |
|---|---|---|---|---|---|---|
| Q2 2026 | 86 | +1 | 73.72M | $1.63B | +7 | −5 |
| Q1 2026 | 87 | -4 | 78.51M | $1.42B | +7 | −12 |
| Q4 2025 | 92 | 0 | 87.58M | $1.71B | +2 | −1 |
| Q3 2025 | 18 | +1 | 57.06M | $721.88M | +1 | −1 |
| Q2 2025 | 15 | +2 | 34.50M | $328.45M | +2 | — |
| Q1 2025 | 10 | -1 | 12.46M | $130.33M | +1 | −2 |
| Q4 2024 | 11 | 0 | 14.93M | $351.71M | +1 | −1 |
| Q3 2024 | 10 | -2 | 10.58M | $380.14M | +1 | −3 |
| Q2 2024 | 12 | — | 13.13M | $463.42M | — | — |
| # | Manajer | Saham | Δ saham | Nilai | Bobotnya | Dipegang | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 4.32M | — | $152.31M | 0.2% | n/c | 1 | SEC ↗ |
| 2 | Adage Capital Partners ✦ | 3.33M | — | $117.45M | 0.2% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 2.37M | — | $83.50M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 2.37M | — | $83.50M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (pasif) | 1.77M | — | $62.64M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (pasif) | 1.77M | — | $62.64M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Point72 Asset Management ✦ | 357.52K | — | $12.62M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Marshall Wace ✦ | 273.57K | — | $9.65M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 226.42K | — | $7.99M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 226.42K | — | $7.99M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 226.42K | — | $7.99M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 226.42K | — | $7.99M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 159.15K | — | $5.62M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 126.00K | — | $4.45M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Norges Bank ✦ (pasif) | 107.09K | — | $3.78M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 88.42K | — | $3.12M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 8.49K | — | $299,788 | 0.0% | n/c | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 8.49K | — | $299,788 | 0.0% | n/c | 1 | SEC ↗ |
"Bobot mereka" = porsi posisi dari total nilai ekuitas 13F yang dilaporkan manajer tersebut — ukuran keyakinan. ✦ = manajer yang dikurasi.
Pembeli baru
| Tidak ada pembeli terlacak baru kuartal ini. |
Telah keluar
| Tidak ada keluar yang terlacak kuartal ini. |
Konteks pasar penuh: di SEMUA filer 13F (data terstruktur SEC, Q1 2026): 226 pemegang, 184.59M saham, $2.74B dilaporkan. Ini adalah periode berbeda yang lebih lama dibandingkan angka semesta yang dilacak di atas, dan keduanya tidak pernah dicampur.
Apa lagi yang paling sering dimiliki oleh pemegang efek ini yang dilacak — berdasarkan jumlah kepemilikan bersama, bukan hubungan fundamental.
Pembelian di pasar terbuka (P)
Tidak ada pembelian insider di pasar terbuka dalam jendela cakupan kami.
Penjualan di pasar terbuka (S)
Director · 1.36M lbr · $33.99M
Director · 478.38K lbr · $11.96M
Director · 322.46K lbr · $8.06M
Director · 63.64K lbr · $1.67M
Officer · 1.80K lbr · $47,225
Officer · 1.56K lbr · $40,892
Officer, Director · 4.99K lbr · $131,032
Officer · 226 lbr · $5,939
Director · 268.35K lbr · $7.03M
Director · 94.42K lbr · $2.47M
Penghargaan, eksekusi, dan pemotongan pajak tidak pernah dihitung sebagai pembelian atau penjualan di sini. Metodologi